ijms-logo

Journal Browser

Journal Browser

Molecular Approaches for Understanding Dengue Disease

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 May 2022) | Viewed by 3452

Special Issue Editors


E-Mail Website
Guest Editor
Environment and Infectious Risks Unit, Arbovirus Group, Institut Pasteur, 25, rue Dr Roux, 75724 Paris CEDEX 15, France
Interests: mosquito biology; tick; saliva; vector competence; arbovirus

E-Mail Website
Guest Editor
Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249. Technology platform CYROI, 2 rueMaxime Rivière, 97491 Sainte-Clotilde, La Réunion, France
Interests: molecular virology; mosquito-borne RNA virus; viral pathogenicity; viral disease; host-virus interactions; viral diagnosis; vaccine; antiviral compounds
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Dengue disease is the most prevalent mosquito-borne viral infection in humans. Dengue incidence has dramatically increased in the last two decades, and dengue burden represents a real threat to affected tropical and subtropical countries worldwide. Mosquito-borne dengue virus (DENV) is an enveloped single-stranded positive RNA virus belonging to the Flavivirus genus of the Flaviviridae family. The four different serotypes of DENV, DENV-1 to DENV-4, can cause a wide spectrum of clinical illnesses ranging from self-limited dengue fever to severe dengue (dengue hemorrhagic fever and dengue shock syndrome) with fatal consequences. No approved antiviral therapeutic agents are available to treat patients with severe dengue disease. An efficient vaccine is expected to afford a long-term protective immunity against the four DENV serotypes. The mechanisms underlying dengue disease are complex, and understanding the pathogenic basis of severe dengue is challenging. Vector transmission of DENV, pathogenic characteristics of viral strain, predisposing genetic determinants, and comorbidities such as chronic diseases associated to metabolic disorders as well as the immune status of individuals have been identified as risk factors for the development of severe dengue. There is a real need of innovative strategies to reduce the incidence of DENV infection and prevent the risk of severe dengue. Consequently, the development of dengue control strategies involves a better knowledge of the biology of emerging viral strains in relation with their mosquito vectors as well as molecular mechanisms involved in the immunopathogenesis of severe dengue.

In this Special Issue, the contributors are warmly invited to publish their works focusing on molecular mechanisms associated with dengue disease.

Dr. Valérie Choumet
Prof. Philippe Desprès
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dengue disease
  • severe dengue
  • viral pathogenesis
  • viral pathogenicity
  • mosquito vector–virus interaction
  • human host–virus interactions

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 3948 KiB  
Article
Development and Characterization of a Multiplex Assay to Quantify Complement-Fixing Antibodies against Dengue Virus
by Eduardo J. M. Nascimento, Brooke Norwood, Allan Parker, Ralph Braun, Eloi Kpamegan and Hansi J. Dean
Int. J. Mol. Sci. 2021, 22(21), 12004; https://doi.org/10.3390/ijms222112004 - 05 Nov 2021
Cited by 4 | Viewed by 2842
Abstract
Antibodies capable of activating the complement system (CS) when bound with antigen are referred to as “complement-fixing antibodies” and are involved in protection against Flaviviruses. A complement-fixing antibody test has been used in the past to measure the ability of dengue virus [...] Read more.
Antibodies capable of activating the complement system (CS) when bound with antigen are referred to as “complement-fixing antibodies” and are involved in protection against Flaviviruses. A complement-fixing antibody test has been used in the past to measure the ability of dengue virus (DENV)-specific serum antibodies to activate the CS. As originally developed, the test is time-consuming, cumbersome, and has limited sensitivity for DENV diagnosis. Here, we developed and characterized a novel multiplex anti-DENV complement-fixing assay based on the Luminex platform to quantitate serum antibodies against all four serotypes (DENV1-4) that activate the CS based on their ability to fix the complement component 1q (C1q). The assay demonstrated good reproducibility and showed equivalent performance to a DENV microneutralization assay that has been used to determine DENV serostatus. In non-human primates, antibodies produced in response to primary DENV1-4 infection induced C1q fixation on homologous and heterologous serotypes. Inter-serotype cross-reactivity was associated with homology of the envelope protein. Interestingly, the antibodies produced following vaccination against Zika virus fixed C1q on DENV. The anti-DENV complement fixing antibody assay represents an alternative approach to determine the quality of functional antibodies produced following DENV natural infection or vaccination and a biomarker for dengue serostatus, while providing insights about immunological cross-reactivity among different Flaviviruses. Full article
(This article belongs to the Special Issue Molecular Approaches for Understanding Dengue Disease)
Show Figures

Figure 1

Back to TopTop